Blood Cancer Clinical Trials

10 recruiting

Frequently Asked Questions

Common questions about Blood Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 1

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

Leukemia, Lymphocytic, AcuteBlood CancerMyeloid Leukemia, Acute+8 more
National Cancer Institute (NCI)86 enrolled1 locationNCT06904066
Recruiting
Phase 1Phase 2

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

LeukemiaBlood CancersBlood Cancer+1 more
Jacqueline Garcia, MD31 enrolled2 locationsNCT07148180
Recruiting
Not Applicable

DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics

Multiple MyelomaLymphomaLeukemia+2 more
UNC Lineberger Comprehensive Cancer Center500 enrolled1 locationNCT06296368
Recruiting
Not Applicable

A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties

LymphomaLeukemiaMyeloma+1 more
Memorial Sloan Kettering Cancer Center60 enrolled7 locationsNCT07052916
Recruiting
Phase 1Phase 2

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Multiple MyelomaNHLRefractory Non-Hodgkin Lymphoma+4 more
Indapta Therapeutics, INC.128 enrolled12 locationsNCT06119685
Recruiting
Not Applicable

Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)

LeukemiaBlood Cancer
Dana-Farber Cancer Institute40 enrolled1 locationNCT06469307
Recruiting

Better Leukemia Diagnostics Through AI (BELUGA)

LymphomaMinimal Residual DiseaseLeukemia+2 more
Munich Leukemia Laboratory25,000 enrolled1 locationNCT04466059
Recruiting
Not Applicable

Early Integration of Palliative and Supportive Care in Cellular Therapy

Multiple MyelomaLymphomaLeukemia+3 more
Alberta Health Services, Calgary152 enrolled1 locationNCT05190653
Recruiting
Not Applicable

Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy

Multiple MyelomaLymphomaLeukemia+2 more
Massachusetts General Hospital90 enrolled1 locationNCT05646576
Recruiting

European Rare Blood Disorders Platform (ENROL)

LeukemiaMyelomaAnemia+9 more
Hospital Universitari Vall d'Hebron Research Institute37,090 enrolled1 locationNCT06250595
Recruiting

The Leukemia and Lymphoma Society (LLS) National Research Registry

Blood Cancer
Blood Cancer United1,000 enrolled1 locationNCT04806295